With $77M series B, condensates company Dewpoint aiming for proof of concept

Dewpoint’s $77 million series B round affords the company “breathing room to make good decisions” as it chooses programs to develop and partner based on the science of biomolecular condensates, CEO Amir Nashat told BioCentury.

The company hopes to gain clinical proof of concept for at least one program, likely in oncology or neuroscience, as it continues to learn about how condensates are implicated in disease states...